Objective: The potential development of a noninvasive marker predicting nonalcoholic steatohepatitis (NASH).
Methods: Thirty patients with biopsy-proven nonalcoholic fatty liver disease were evaluated by numerous anthropometric, clinical and biochemical parameters.
Results: Serum glutamic oxaloacetic transaminase (SGOT; p = 0.